Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter June 1, 2005

Apolipoprotein H (apoH)-dependent autoantibodies and apoH protein polymorphism in selected patients showing lupus anticoagulant activity

Željka Vogrinc, Milica Trbojević-Čepe, Désirée Coen, Ksenija Vitale and Ana Stavljenić-Rukavina

Abstract

Apolipoprotein H (apoH) is considered to be a necessary cofactor for the binding of certain antiphospholipid antibodies to anionic phospholipids. Some apoH-dependent antiphospholipid antibodies also exert lupus anticoagulant (LA) activity, which seems to depend on antiphospholipid antibody epitope specificity. The aim of this study was to evaluate whether the presence of less frequent apoH alleles may induce structural or conformational changes in these “LA-dependent” regions that may initiate more frequent autoimmune responses in subjects. We selected patients with confirmed LA activity and none or low titers of anticardiolipin antibodies that had been sent to the laboratory for routine antiphospholipid antibody determination. Many of them had some clinical manifestation of antiphospholipid syndrome. Antibodies to apoH were determined with a commercially available anticardiolipin/apoH ELISA kit. ApoH protein polymorphism (apoH phenotype) was demonstrated by isoelectric focusing and immunoblotting. Our results showed that 47/74 (63.5%) of our selected LA-positive patients also had elevated apoH-dependent antiphospholipid antibody titers. These results point to two subgroups of patients according to the LA potency of apoH-dependent antibodies. A strong positive correlation (non-linear or linear) for apoH-dependent antibody titers and LA activity was observed in both subgroups of patients. In this study, we did not find significant differences in the distribution of apoH phenotypes among control subjects and patients with apoH-dependent/LA-positive auto- antibodies.


Corresponding author: Željka Vogrinc, Clinical Institute of Laboratory Diagnosis, Zagreb University School of Medicine and Clinical Hospital Center, Kišpatićeva 12, 10000 Zagreb, Croatia Phone: +385-1-2388011, Fax: +385-1-2312079,

References

1 Lozier J, Takahashi N, Putnana FW. Complete amino acid sequence of human plasma β2-glycoprotein I. Proc Natl Acad Sci USA 1984; 81: 3640–4. 10.1073/pnas.81.12.3640Search in Google Scholar

2 Kato H, Enjoji K. Amino acid sequence and location of the disulfide bonds in bovine glycoprotein I: the presence of five sushi domains. Biochemistry 1991; 30: 11687–94. 10.1021/bi00114a012Search in Google Scholar

3 Kamboh MI, Ferrell RE, Sepehrnia B. Genetic study of human apolipoproteins. IV. Structural heterogeneity of apolipoprotein H (β2-glycoprotein I). Am J Hum Genet 1988; 42: 452–7. Search in Google Scholar

4 Sanghera DK, Kristensen T, Hamman RF, Kamboh MI. Molecular basis of the apolipoprotein H (β 2-glycoprotein I) protein polymorphism. Hum Genet 1997; 100: 57–62. 10.1007/s004390050465Search in Google Scholar

5 Cleve H, Vogt U, Kamboh MI. Genetic polymorphism of apolipoprotein H (β2-glycoprotein I) in African blacks from the Ivory Coast. Electrophoresis 1992; 13: 849–51. 10.1002/elps.11501301185Search in Google Scholar

6 Kamboh MI, Ferrell RE. Apolipoprotein H polymorphism and its role in lipid metabolism. Adv Lipid Res 1991; 1: 9–18. Search in Google Scholar

7 Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 569–73. 10.1046/j.1365-2249.1997.d01-948.xSearch in Google Scholar

8 Schousboe I. Binding of β 2-glycoprotein I to platelets: effect of adenylate cyclase activity. Thromb Res 1980; 19: 225–37. 10.1016/0049-3848(80)90421-1Search in Google Scholar

9 Wurm H. β 2-Glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem 1984; 16: 511–5. 10.1016/0020-711X(84)90168-XSearch in Google Scholar

10 Kroll J, Larsen JK, Loft H, Ezban M, Wallewick K, Faber M. DNA binding proteins in Yoshida ascites tumor fluid. Biochem Biophys Acta 1976; 434: 490–501. 10.1016/0005-2795(76)90239-7Search in Google Scholar

11 Sanghera DK, Wagenknecht DR, McIntyre JA, Kamboh MI. Identification of structural mutations in the fifth domain of apolipoprotein H ([beta] 2-glycoprotein I) which affect phospholipid binding. Hum Mol Gen 1997; 6: 311–6. 10.1093/hmg/6.2.311Search in Google Scholar PubMed

12 Kamboh MI. Genetics of apolipoprotein H (beta (2)-glycoprotein I) and anionic phospholipid binding. Lupus 1998; 7(Suppl 2): S10–3. 10.1177/096120339800700203Search in Google Scholar PubMed

13 Brighton TA, Hogg PJ, Dai YP, Murray BH, Chong BH, Chesterman CN. β2-Glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant. Br J Haematol 1996; 93: 185–94. 10.1046/j.1365-2141.1996.446981.xSearch in Google Scholar

14 Giles IP, Isenberg DA, Latchman DS, Rahman A. How do antiphospholipid antibodies bind β 2-glycoprotein I?[Review] Arthritis Rheumatism 2003; 48: 2111–21. 10.1002/art.11101Search in Google Scholar

15 Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544–7. 10.1016/0140-6736(90)91374-JSearch in Google Scholar

16 Reddel SW, Krilis SA. Testing for and clinical significance of anticardiolipin antibodies. Clin Diagn Lab Immunol 1999; 6: 775–82. 10.1128/CDLI.6.6.775-782.1999Search in Google Scholar PubMed PubMed Central

17 Audrain MA, El Kouri D, Hamidou MA, Mioche L, Ibara A, Langlois ML, et al. Value of autoantibodies to β 2-glycoprotein 1 in the diagnosis of antiphospholipid syndrome. Rheumatology 2002; 41: 550–3. 10.1093/rheumatology/41.5.550Search in Google Scholar PubMed

18 Hanly JG. Antiphospholipid syndrome: an overview. Can Med Assoc J 2003; 168: 1675–88. Search in Google Scholar

19 Wisløff F, Jacobsen EM, Liestøl S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 2003; 2121: 1–9. Search in Google Scholar

20 Alarcón-Segovia DA, Cabral AR. Clinical associations of antibodies to phospholipids and/or their protein cofactors. In: Shoenfeld Y, editor. The decade of autoimmunity. Amsterdam: Elsevier Science BV, 1999:75–9. Search in Google Scholar

21 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a stemic review of the literature. Blood 2003; 101: 1827–32. 10.1182/blood-2002-02-0441Search in Google Scholar PubMed

22 Arnout J. Risk for thrombosis linked to the target antigen of a lupus anticoagulant? Thromb Haemost 2004; 2: 697–9. 10.1111/j.1538-7836.2004.00752.xSearch in Google Scholar PubMed

23 Takeya H, Mori, T, Gabazza EC, Kuroda K, Deguchi H, Matsuura E, et al. Anti-β2-glycoprotein I (β 2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the β 2GPI binding to phospholipids. J Clin Invest 1997; 99: 2260–8. 10.1172/JCI119401Search in Google Scholar PubMed PubMed Central

24 Galli M, Comfurius P, Barbui T, Zwaal RRA, Bevers EM. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68: 297–300. 10.1055/s-0038-1656368Search in Google Scholar

25 Sheng Y, Hanly JG, Reddel SW, Kouts S, Guerin J, Koike T, et al. Detection of “antiphospholipid” antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding beta(2)-glycoprotein I and prothrombin. Clin Exp Immunol 2001; 124: 502–8. 10.1046/j.1365-2249.2001.01555.xSearch in Google Scholar PubMed PubMed Central

26 Matsuura E, Inagaki J, Kasahara H, Yamamoto D, Atsumi T, Kobayashi K, et al. Proteolytic cleavage of β2-glycoprotein I: reduction of antigenicity and the structural relationship. Int Immunol 2000; 12: 1183–92. 10.1093/intimm/12.8.1183Search in Google Scholar PubMed

27 Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci USA 1998; 95: 15542–6. 10.1073/pnas.95.26.15542Search in Google Scholar PubMed PubMed Central

28 Sheng Y, Kandiah DA, Krilis SA. Anti-beta 2-glycoprotein I autoantibodies from patients with the “antiphospholipid” syndrome bind to beta-2 glycoprotein I with low affinity: dimerization of beta-2 glycoprotein I induces a significant increase in anti-beta-2 glycoprotein I antibody affinity. J Immunol 1998; 161: 2038–43. Search in Google Scholar

29 Iverson GM, Matsuura E, Victoria EJ, Cockerill KA, Linnik MD. The orientation of beta-2-GPI on the plate is important for the binding of anti-beta-2-GPI autoantibodies by ELISA. J Autoimmun 2002; 18: 289–97. 10.1006/jaut.2002.0590Search in Google Scholar PubMed

30 Gharavi AE, Harris EN, Asherson RA, Hughes GRV. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987; 46: 1–6. 10.1136/ard.46.1.1Search in Google Scholar PubMed PubMed Central

31 Pengo V, Brocco T, Biasiolo A, Rampazzo P, Carraro P, Zamarchi R. Procoagulant effect of anti-β2-glycoprotein I antibodies with lupus anticoagulant activity. Blood 1999; 94: 3814–9. 10.1182/blood.V94.11.3814Search in Google Scholar

32 Pengo V, Biasiolo A, Pegoraro C, Iliceto S. A two-step coagulation test to identify antiβ2-glycoprotein I lupus anticoagulants. J Thromb Haemost 2004; 5: 702–7. 10.1111/j.1538-7836.2004.00712.xSearch in Google Scholar PubMed

33 Arnout J. Risk for thrombosis linked to the target antigen of a lupus anticoagulant. J Thromb Haemost 2004; 2: 697–702. 10.1111/j.1538-7836.2004.00752.xSearch in Google Scholar PubMed

34 Ichikawa K, Khamashta MA, Koike T, Matsura E, Hughes GR. β2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994; 37: 1453–61. 10.1002/art.1780371008Search in Google Scholar PubMed

35 Arnout J, Vermylen J. Mechanism of action of β 2-glycoprotein I-dependent lupus anticoagulants. Lupus 1998; 7(Suppl 2): S23–8. 10.1177/096120339800700206Search in Google Scholar PubMed

36 Lutters BC, Meijers JC, Derksen RH, Arnout J, de Groot PG. Dimers of β 2-glycoprotein I mimic in vitro effects of β 2-glycoprotein I-anti-β 2-glycoprotein I antibody complexes. J Biol Chem 2001; 276: 3060–7. 10.1074/jbc.M008224200Search in Google Scholar PubMed

37 Gushiken FC, Le A, Arnett FC, Thiagarajan P. Polymorphisms β 2-glycoprotein I: phospholipid binding and multimeric structure. Thromb Res 2003; 108: 175–80. 10.1016/S0049-3848(02)00392-4Search in Google Scholar

Received: 2004-3-19
Accepted: 2004-10-7
Published Online: 2005-6-1
Published in Print: 2005-1-1

©2005 by Walter de Gruyter Berlin New York